47 related articles for article (PubMed ID: 30170680)
1. Interesting features of Cardiac Magnetic Resonance in a Case of Hypereosinophilic Syndrome Secondary to Toxocariasis.
Asadian S; Rezaeian N; Asl Fallah S
Clin Case Rep; 2021 Nov; 9(11):e05043. PubMed ID: 34765215
[TBL] [Abstract][Full Text] [Related]
2. A case report of a 40-year-old woman with endomyocardial fibrosis in a non-tropical area: from initial presentation to high urgent heart transplantation.
Wagner G; Haumer M; Poelzl G; Wiedemann D; Kliegel A; Ullrich R; Gartlehner G; Zuckermann A; Müller L; Mayr H; Moertl D
BMC Cardiovasc Disord; 2019 Dec; 19(1):302. PubMed ID: 31881943
[TBL] [Abstract][Full Text] [Related]
3. Endomyocardial Fibrosis: an Update After 70 Years.
Mocumbi AO; Stothard JR; Correia-de-Sá P; Yacoub M
Curr Cardiol Rep; 2019 Nov; 21(11):148. PubMed ID: 31758352
[TBL] [Abstract][Full Text] [Related]
4. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter L; Zellweger MJ; Bremerich J
Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
[No Abstract] [Full Text] [Related]
5. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
6. Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure.
Bonou M; Kapelios CJ; Benetos G; Moyssakis I; Giannakopoulou N; Diamantopoulos P; Korkolopoulou P; Variami E; Barbetseas J
Can J Cardiol; 2017 May; 33(5):688.e5-688.e7. PubMed ID: 28347583
[TBL] [Abstract][Full Text] [Related]
7. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
[No Abstract] [Full Text] [Related]
8. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
[No Abstract] [Full Text] [Related]
9. Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia.
Strong C; Abecasis J; Afonso C; Trabulo M; Gouveia R
Can J Cardiol; 2018 Sep; 34(9):1233.e13-1233.e15. PubMed ID: 30170680
[TBL] [Abstract][Full Text] [Related]
10. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
Roufosse F; Goldman M; Cogan E
Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
[TBL] [Abstract][Full Text] [Related]
11. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Borbényi Z
Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
[TBL] [Abstract][Full Text] [Related]
12. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.
Bain BJ; Fletcher SH
Immunol Allergy Clin North Am; 2007 Aug; 27(3):377-88. PubMed ID: 17868855
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
